Lucid Announces Closing of $300 Million Investment from Uber
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Canaccord Genuity on Lucid Diagnostics Inc (LUCD): 'we believe the stock does not reflect the company's long-term growth potential'
September 5, 2025 5:16 AM EDT(Updated - September 5, 2025 5:32 AM EDT)
Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD)
The analyst comments "We reiterate our BUY rating on Lucid Diagnostics (LUCD) shares and maintain our price target at $3. Intraday on Thursday, September 4, MolDX-participating Medicare Administrative Contractors (MACs) convened a MolDX Contractor Advisory Committee (CAC)... More
